BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24170366)

  • 21. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus.
    Massad LS; Evans CT; Minkoff H; Watts DH; Strickler HD; Darragh T; Levine A; Anastos K; Moxley M; Passaro DJ
    Obstet Gynecol; 2004 Nov; 104(5 Pt 1):1077-85. PubMed ID: 15516404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme.
    Luyten A; Buttmann-Schweiger N; Luyten K; Mauritz C; Reinecke-Lüthge A; Pietralla M; Meijer CJ; Petry KU
    Int J Cancer; 2014 Sep; 135(6):1408-16. PubMed ID: 24519782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term observational approach in women with histological diagnosis of cervical low-grade squamous intraepithelial lesion: an Italian multicentric retrospective cohort study.
    Ciavattini A; Serri M; Di Giuseppe J; Liverani CA; Gardella B; Papiccio M; Delli Carpini G; Morini S; Clemente N; Sopracordevole F
    BMJ Open; 2019 Jul; 9(7):e024920. PubMed ID: 31272971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
    Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
    Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Underlying histopathology of HIV-infected women with squamous cell abnormalities on cervical cytology.
    Suwankanta N; Kietpeerakool C; Srisomboon J; Khunamornpong S; Siriaunkgul S
    Asian Pac J Cancer Prev; 2008; 9(3):441-4. PubMed ID: 18990018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
    Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
    Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women.
    Massad LS; Xie X; Burk RD; D'Souza G; Darragh TM; Minkoff H; Colie C; Burian P; Palefsky J; Atrio J; Strickler HD
    Am J Obstet Gynecol; 2016 Mar; 214(3):354.e1-6. PubMed ID: 26433170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized clinical trial comparing cervical dysplasia treatment with cryotherapy vs loop electrosurgical excision procedure in HIV-seropositive women from Johannesburg, South Africa.
    Smith JS; Sanusi B; Swarts A; Faesen M; Levin S; Goeieman B; Ramotshela S; Rakhombe N; Williamson AL; Michelow P; Omar T; Hudgens MG; Firnhaber C
    Am J Obstet Gynecol; 2017 Aug; 217(2):183.e1-183.e11. PubMed ID: 28366730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India.
    Sahasrabuddhe VV; Bhosale RA; Kavatkar AN; Nagwanshi CA; Joshi SN; Jenkins CA; Shepherd BE; Kelkar RS; Sahay S; Risbud AR; Vermund SH; Mehendale SM
    Int J Cancer; 2012 Jan; 130(1):234-40. PubMed ID: 21387289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.